Investor Resources

Quick Explore

Investor Resources Results for 2026-2027
icon-pdf
Press Release - Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US
03rd Sep 2026
icon-pdf
Newpaper Advertisement regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares
02nd Sep 2026
icon-pdf
Q1 FY27 Press Release
02nd Sep 2026
icon-pdf
Press Release - Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)
31st Aug 2026
icon-pdf
Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA
28th Aug 2026
icon-pdf
Restructuring: Transfer of Ownership of Aspergen Inc., USA to Aspergen Limited, India
27th Aug 2026
icon-pdf
Schedule of Analysts/ Institutional Investor Meetings
27th Aug 2026
icon-pdf
Allotment of 5,281 equity shares under ESOS 2013-A Scheme and the Cipla ESAR Scheme 2021 of the Company
26th Aug 2026
icon-pdf
USFDA inspection at Company’s manufacturing facility in Pithampur, India
25th Aug 2026
icon-pdf
NCLT Interim Order on Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited
19th Aug 2026
 
BSE and NSE Quotes by TradingView

The displayed data is not in real time and may have streaming delays.